These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38579618)

  • 1. Cryo-EM structure of P-glycoprotein bound to triple elacridar inhibitor molecules.
    Hamaguchi-Suzuki N; Adachi N; Moriya T; Yasuda S; Kawasaki M; Suzuki K; Ogasawara S; Anzai N; Senda T; Murata T
    Biochem Biophys Res Commun; 2024 May; 709():149855. PubMed ID: 38579618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R; Agarwal S; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.
    Rowbottom C; Pietrasiewicz A; Tuczewycz T; Grater R; Qiu D; Kapadnis S; Trapa P
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00740. PubMed ID: 33660938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
    Suzuki K; Taniyama K; Aoyama T; Watanabe Y
    Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1.
    Nosol K; Romane K; Irobalieva RN; Alam A; Kowal J; Fujita N; Locher KP
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26245-26253. PubMed ID: 33020312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoprotein.
    Pajeva IK; Sterz K; Christlieb M; Steggemann K; Marighetti F; Wiese M
    ChemMedChem; 2013 Oct; 8(10):1701-13. PubMed ID: 23943604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
    Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
    Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
    Sane R; Mittapalli RK; Elmquist WF
    J Pharm Sci; 2013 Apr; 102(4):1343-54. PubMed ID: 23334925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein.
    Chufan EE; Kapoor K; Ambudkar SV
    Biochem Pharmacol; 2016 Feb; 101():40-53. PubMed ID: 26686578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.
    Bauer M; Karch R; Zeitlinger M; Stanek J; Philippe C; Wadsak W; Mitterhauser M; Jäger W; Haslacher H; Müller M; Langer O
    J Nucl Med; 2013 Aug; 54(8):1181-7. PubMed ID: 23833270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
    Lagas JS; van Waterschoot RA; van Tilburg VA; Hillebrand MJ; Lankheet N; Rosing H; Beijnen JH; Schinkel AH
    Clin Cancer Res; 2009 Apr; 15(7):2344-51. PubMed ID: 19276246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice.
    Abdallah IM; Al-Shami KM; Yang E; Kaddoumi A
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence That P-glycoprotein Inhibitor (Elacridar)-Loaded Nanocarriers Improve Epidermal Targeting of an Anticancer Drug via Absorptive Cutaneous Transporters Inhibition.
    Giacone DV; Carvalho VFM; Costa SKP; Lopes LB
    J Pharm Sci; 2018 Feb; 107(2):698-705. PubMed ID: 28935591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer.
    Bar-Zeev M; Kelmansky D; Assaraf YG; Livney YD
    Eur J Pharm Biopharm; 2018 Dec; 133():240-249. PubMed ID: 30367935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly Eribulin-resistant KBV20C Oral Cancer Cells Can Be Sensitized by Co-treatment with the Third-generation P-Glycoprotein Inhibitor, Elacridar, at a Low Dose.
    Park Y; Son JY; Lee BM; Kim HS; Yoon S
    Anticancer Res; 2017 Aug; 37(8):4139-4146. PubMed ID: 28739698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of the antigen-binding fragment of a monoclonal antibody specific for the multidrug-resistance-linked ABC transporter human P-glycoprotein.
    Esser L; Shukla S; Zhou F; Ambudkar SV; Xia D
    Acta Crystallogr F Struct Biol Commun; 2016 Aug; 72(Pt 8):636-41. PubMed ID: 27487928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies.
    Dash RP; Jayachandra Babu R; Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):915-933. PubMed ID: 28374336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retina Compatible Interactions and Effective Modulation of Blood Ocular Barrier P-gp Activity by Third-Generation Inhibitors Improve the Ocular Penetration of Loperamide.
    Janga KY; Tatke A; Shukla S; Lamichhane SP; Avula B; Wang X; Jablonski MM; Khan IA; Majumdar S
    J Pharm Sci; 2018 Aug; 107(8):2128-2135. PubMed ID: 29678592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.